Efficacy and Safety of Paricalcitol Therapy for Kidney Transplantation Recipients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Bo Wang, Yao Liu, Bangcai Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis of randomized controlled trials assessed paricalcitol versus inactive control in kidney transplant recipients. Six trials involving 482 recipients were included. Paricalcitol reduced parathyroid hormone (SMD, -0.74; 95% CI, -1.23 to -0.24; p = .01; I² = 52%), while serum calcium increased (SMD, 0.36; 95% CI, 0.03 to 0.68; p = .04; I² = 25%) and hypercalcemia was more frequent (RR, 3.71; 95% CI, 1.21 to 11.36; p = .03; I² = 0%). Effects on proteinuria and rejection were inconclusive.
Key findings
- Paricalcitol reduced parathyroid hormone: SMD, -0.74; 95% CI, -1.23 to -0.24; p = .01; I² = 52%.
- Serum calcium increased with paricalcitol: SMD, 0.36; 95% CI, 0.03 to 0.68; p = .04; I² = 25%.
- Hypercalcemia was more frequent with paricalcitol: RR, 3.71; 95% CI, 1.21 to 11.36; p = .03; I² = 0%.
- Proteinuria reduction was not clear (SMD, -0.22; 95% CI, -0.50 to 0.06; p = .10), and rejection findings were inconclusive.
Why it matters
The findings indicate a short-term biochemical benefit alongside a measurable calcium-related safety concern in kidney transplant recipients. They also show that evidence for proteinuria, rejection, graft survival, and patient outcomes remains insufficient. This distinction is important when interpreting paricalcitol’s potential benefits: changes in parathyroid hormone do not establish improvement in graft or patient outcomes.
What to keep in mind
The evidence comprised few, clinically heterogeneous randomized trials with short follow-up, limiting conclusions about graft survival and patient outcomes.